All News
Imaging Reveals Anatomical Focus of Inflammation in PMR
Two studies presented at ACR18 have used imaging to examine one of the key unanswered questions in polymyalgia rheumatica - what structures are the focus of inflammation in the disease – and demonstrated that peritendineal involvement is ubiquitous in and distinctive of PMR.
Read ArticleRheumNow ACR Week in Review: ACR Wrap-Up (10.26.18)
This past week in Chicago gave us a plethora of new and eye-opening research, people, KOLs, exhibits, sessions, guidelines, posters and a never-ending supply of coffee served in small paper cups. ACR 2018 highlights for me included:
Read ArticleACR 2018 - Day 4 Report
Highlights from Tuesday and Wednesday (days 3 and 4) from the ACR annual meeting include: the important and impactful abstracts covered by the Rheumatology Roundup session; upadacitinib clinical trials; and the baricitinib CV and VTE safety analysis.
Read ArticleHydroxychloroquine Dosing: the Great Debate
Rheumatologists tend to be a conservative bunch of people. We’re law abiding and we (mostly) follow guidelines. Which is fine when they are in the best interests of our patients, but what do we do when we fundamentally disagree?
Read ArticleIs DAS28 and HAQ-DI Headed for the Graveyard?
Dr. Joseph Smolen delivered one of the most elegant and informative talk on rheumatoid arthritis at this ACR’s meeting as a tribute to Dr. Paul Klemperer. Dr. Smolen led us on a journey, and had us feeling content with what we are doing in practice as we walked with him from historical discoveries of RA through new drug development. Then Dr. Smolen did the unthinkable: he made us crash!
Read ArticleEmerging Trends in the Treatment of Rheumatoid Arthritis
ACR 2018 - Day 1 Report
RheumNow is in Chicago covering the ACR annual meeting. Here are the highlights from Sunday (day one). Be sure to check our complete coverage, including articles, video reports and tweets, at acr18.rheumnow.com.
Read ArticleHigh Dose Flu Vaccine for Patients Younger Than 65?
We are diving head first into flu season and we need to prepare ourselves. Last year we now know that 80,000 Americans died from influenza.
Read ArticleICI-Induced Inflammatory Arthritis and Shared Epitope Alleles
Immune checkpoint inhibitors (ICI) have changed the hematology/oncology world. However, their AEs from a rheumatologic standpoint are still being evaluated and at this time, genetic risk factors for inflammatory arthritis due to ICI are not well understood. Dr. Cappelli et al evaluated a possible connection with HLA typing at their institution.
Read ArticleNEJM Debate on Medical Marijuana for Chronic Pain
This week’s NEJM features a case discussion and debate over whether medical marijuana should be used to treat chronic pain. The debate focuses on a 31-year-old woman with long-standing complex regional pain syndrome in her leg and foot.
Read ArticleUpdate on Immune Checkpoint Inhibitor Toxicity
JAMA has a 2018 update/review of the safety issues seen with mmune checkpoint inhibitors (ICIs) - important new cancer therapies, with 14 cancer indications, that have significantly improved survival in several. ICIs are monoclonal antibodies that block inhibitors of T-cell activation and function.
Read ArticleIL-6 for Adult Still's: A New Option?
Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met, Japanese researchers reported.
Read ArticleNSAIDs OK for Certain High-Risk Groups?
Some patients typically contraindicated for prescription nonsteroidal anti-inflammatory drug (NSAID) use may be able to take them with no increased risk of harm, according to a large observational study.
Read ArticleRheumNow Week in Review – Vitamin D Falls Again (10.4.18)
Dr. Jack Cush reviews the news from the past week on RheumNow.com.
Read ArticlePredictive Risk Factors for Uveitis in JIA
Researchers from Germany have studied a large cohort of juvenile idiopathic arthritis (JIA) patients and shown that JIA disease activity scores and laboratory biomarkers could be used to better define the group of JIA patients at high risk of uveitis onset.
Read ArticleElder Rheumatoids Less Likely to Receive Biologics
Multiple studies have shown that elderly rheumatoid arthritis (RA) patients tend to be under-treated and receive DMARD therapies less often than younger RA patients.
Read ArticleLong-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Only inhibitors of IL-1 (canakinumab) and IL-6 (tocilizumab) are FDA approved for use in children with systemic onset juvenile idiopathic arthritis (sJIA). Now, long-term data from the extension studies from two phase III studies shows that canakinumab yields long-term improvements with reduced glucocorticoid dosing with no new safety findings with long-term use.
Read ArticleDefining Refractory Rheumatoid Arthritis
Researchers from the British Society for Rheumatology Biologics (BSRBR) set out to define under what circumstances will rheumatoid arthritis (RA) patients manifest biologic disease-modifying antirheumatic drugs (bDMARDs) refractory disease.
Read ArticleNeuropathic Like Knee Pain
Fernandez and colleagues have shed further light on a significant subset of patients with knee pain - specifically, those with neuropathic like knee pain (NKP) that includes those with knee pain modified by central and peripheral neurologic dysfunction.
Read ArticleRheumNow Week in Review – I Wanna New Drug (9.28.18)
Dr. Jack Cush reviews the news from the past week on RheumNow.com, including news on inappropriate opioids, pre-clinical RA treatment, DMARDs in Gout, the decline of arthroscopy, and a pain in the mouth.
Read Article